Supreme Court Won't Hear CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court declined CareDx's appeal in its false-advertising battle with Natera, leaving a lower court ruling intact.
The U.S. Supreme Court has shut the door on CareDx, refusing to take up the company's appeal in its ongoing false-advertising clash with Natera. When the high court passes on a case like this, the lower court's decision stands — and that's a significant blow for CareDx heading into whatever comes next.
Natera, the genetic testing company behind the Prospera transplant rejection test, has been locked in a legal war with CareDx over advertising claims in the organ transplant monitoring space. These two are direct competitors, and the stakes are real — both companies are fighting for dominance in a market where clinicians decide which test gets ordered.
Read more Prediction Markets Raise Insider Trading Red Flags for Wall Street →
For traders watching NTRA, a Supreme Court rejection of your rival's appeal is a clean win. It signals legal momentum and removes a layer of uncertainty that was hanging over the stock. CareDx, on the other hand, now has to reassess its legal strategy with fewer options on the table.
False-advertising disputes in biotech aren't just about courtroom drama — they can directly impact sales force messaging, marketing materials, and ultimately revenue. If Natera's claims about its competitor's ads hold up through the legal process, that could constrain how CareDx competes in the field.
The decision reinforces Natera's positioning in the transplant diagnostics space and adds pressure on CareDx at a time when both companies are battling hard for market share. Watch how management on both sides addresses this in upcoming earnings calls. Continue reading at Yahoo Finance.
